bioRxivNeurosciencePreprint
LRRK2 regulates ArfGAP1 membrane localization, activity and neuronal toxicity via phosphorylation within its lipid-sensing ALPS2 motif
Md. Shariful IslamiD, Valentín Cóppola-SegoviaiD, Alessandra Musso, Darren J. MooreiD
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinsons disease (PD). LRRK2 encodes a multi-domain protein containing a Roc GTPase domain and a serine/threonine-directed protein kinase domain, with PD-linked mutations known to enhance LRRK2 kinase activity and neuronal toxicity. Our previous studies identified the Golgi protein, ADP-Ribosylation Factor GTPase-Activating Protein 1 (ArfGAP1), as a novel modifier of LRRK2-induced cellular toxicity, where it can serve as a GAP-like protein and a robust kinase substrate of LRRK2. Here, we further explore the phosphorylation of ArfGAP1 by LRRK2 and its functional consequences. LRRK2 mediates the robust phosphorylation of ArfGAP1 within its lipid-sensing ALPS2 motif at residues Ser284, Thr291 and Thr292. We mutated these three phosphorylation sites, either alone or combined, to create hydrophobic phospho-null or charged phospho-mimicking versions of ArfGAP1. We find that modulating ArfGAP1 phosphorylation impairs its normal capacity to induce Golgi fragmentation upon overexpression in neural cells. Blocking phosphorylation impairs ArfGAP1-induced neurite outgrowth inhibition in primary neurons and protects against the neurotoxic effects of PD-linked G2019S LRRK2. ArfGAP1 interactome analysis in neural cells identifies 114 putative interacting proteins with a proportion of these unexpectedly localized to mitochondria, including the outer membrane proteins Voltage-Dependent Anion Channel (VDAC) 1-3. An ArfGAP1 triple phospho-mimic displays an increased interaction with mitochondrial VDACs owing to the redistribution of ArfGAP1 from the cis-Golgi to the cytoplasm. Promoting ArfGAP1 phosphorylation also blocks the formation of Golgi-derived vesicles following mild ER stress. Our data provides evidence for a complex functional interaction between LRRK2 and ArfGAP1 that serves to regulate ArfGAP1 subcellular localization, protein interactions, activity and neuronal toxicity via LRRK2-mediated phosphorylation of its membrane-binding ALPS2 motif. Our findings support additional validation of ArfGAP1 as a putative therapeutic target for modulating LRRK2-linked PD.
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Regulation between LRRK2 and PP2A signaling in cellular models of Parkinsons disease
Panagiotis S. Athanasopoulos, Anna Memou, … Arjan Kortholt·Biochemical JournalPeer-reviewed·May 14, 2026
- Identification of GEFs and GAPS modulating phosphorylation and abundance of Rab10 by LRRK2-G2019S in neurons
Alison Fellgett, Sean T. Sweeney, … Christopher J. H. Elliott·bioRxiv·May 23, 2023
- Dopaminergic Neurodegeneration Induced by Parkinson's Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase Activity
An Phu Tran Nguyen, Elpida Tsika, … Darren J. Moore·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 6, 2020
- A Feed-forward Pathway Drives LRRK2 kinase Membrane Recruitment and Activation
E. G. Vides, A. Adhikari, … S. R. Pfeffer·bioRxiv·Apr 25, 2022
- Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity
An Phu Tran Nguyen, Roger Moser, … Darren J. Moore·Human Molecular GeneticsPeer-reviewed·Jan 1, 2026
- Neurodegeneration caused by LRRK2-G2019S requires Rab10 in select dopaminergic neurons
Stavroula Petridi, C. Adam Middleton, … Christopher J. H. Elliott·bioRxiv·Mar 22, 2019